Skip to content

Effect of Yu's head acupuncture combination on patients with PSCI and its influence on anxiety, depression and sleep quality

Effect of Yu's head acupuncture combination on patients with PSCI and its influence on anxiety, depression and sleep quality

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110649
Enrollment
Unknown
Registered
2025-10-17
Start date
2023-07-06
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke cognitive impairment

Interventions

Treatment group:Acupuncture

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria for post-stroke cognitive impairment; 2. Age 40-75 years old, gender and education are not limited; 3. First onset, the course of the disease is 2 weeks to 6 months; 4. The condition is stable, the mind is clear, and the compliance is good; 5. Montreal Cognitive Assessment Scale (MoCA) score <26; 6. Informed and voluntary participation in this clinical trial, and the informed consent form for the clinical trial shall be signed by the person or his guardian.

Exclusion criteria

Exclusion criteria: 1.Patients with severe cognitive impairment with a MoCA score of Hamilton or Hamilton Patients with severe anxiety with a score of > 28 on the Erton Anxiety Scale (HAMA); 3.Those who have cognitive impairment, depression, anxiety, and sleep disorders before the stroke event; 4.Cognitive impairment caused by congenital developmental abnormalities, or cognitive impairment caused by other diseases (such as Alzheimer's disease, traumatic brain injury, etc.); 5.Those who have other serious heart, liver, brain, kidney, digestive system, circulatory system and other diseases, or have serious systemic infections and tumors; 6.Those with severe mental illness, metabolic disease, or visual and auditory impairment; 7.Those who have taken drugs to improve cognitive impairment, anxiety, depression, and sleep disorders in the past 3 months or have received treatment in this area.

Design outcomes

Primary

MeasureTime frame
Effective rate;

Secondary

MeasureTime frame
Montreal cognitive assessment;Hamilton Depression ;Hamilton Anxiety ;Pittsburgh sleep quality index;Barthel index;

Countries

China

Contacts

Public ContactJinxia Ni

Dongzhimen Hospital, Beijing University of Chinese Medicine

nijinxia118@126.com+86 84013161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026